港股异动|鲁证期货跌逾5%创新低料中期纯利同比跌55%-60%
格隆汇7月31日丨鲁证期货(1461.HK)今日低开低走,盘中低见0.89港元,创上市以来历史新低。现报0.89港元,跌5.32%,暂成交115万港元,最新总市值8.9亿港元。鲁证期货昨日晚间发布公告称,预计截至6月30日止6个月期间归属于股东净利润较2018年同期下降约55%至60%。业绩预减主要是由于:期内市场利率下调,交易所减免政策变化;受交易所程序化交易基础资源限制,公司程序化交易较去年大幅萎缩;金融产品公允价值变动引起投资收益大幅波动;及为应对中国内地期货市场国际化,新设机构短期内增加了运营成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.